Supportive care

Emergencies in Pediatric Oncology

Volumn , Issue , 2012, Pages 121-141

  MacDonald, Paula ^a  

^a MCMASTER CHILDREN S HOSPITAL   (Canada)

Author keywords

5 HT3receptor; Anticipatory emesis; Candida sp; Electrolyte replacement; Granulocyte colony stimulating factor (G CSF); Medullary bone pain; Myelosuppression; Nausea; Oral magnesium supplementation; Pneumocystis prophylaxis; Prolonged neutropenia; Splenomegaly; Thrombocytopenia; Trimethoprim sulfamethoxazole; Vomiting

Indexed keywords

EID: 84937524004     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1174-1_14     Document Type: Chapter

References (29)

1. rded. Philadelphia, Pa: W.B. Wanders Company;2002:279-318.
2. thed. Philadelphia, Pa: Lippincott Williams & Wilkins;2002:1301-1332.
3. Antonarakis ES, Hain RDW. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice. Archives of Disease in Childhood. 2004;89:877-880.
4. Children’s Oncology Group Supportive Care Guidelines. https://members.childrensoncology- group.org/_files/protocol/standard/SupportiveCareGuidelines.pdf. Accessed November 29, 2010.
5. Cancer Care Ontario: Management of chemotherapy-induced nausea and vomiting. http://www.cancercare.on.ca. Accessed February 1, 2010.
6. Policy for the treatment of chemotherapy induced nausea and vomiting. http://www.yorkshire- cancer-net.org.uk/html/downloads/ycn_hyccn_cyp_haematology_oncology_chemotherapyin- ducednauseaandvomiting_dec2009.pdf. Accessed December 11, 2010.
7. Dupuis LL, Nathan PC. Optimizing emetic control in children receiving antineoplastic therapy. Pediatric Drugs. 2010;12(1):51-61.
8. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. Journal of Clinical Oncology. 2006;24(16):2932-2947.
9. FDA Drug Safety Communication - Abnormal heart rhythms associated with the use of Anzemet (dolasetron mesylate). http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm. Accessed December 21, 2010.
10. Lau E, ed. The Hospital for Sick Children 2009-2010 Drug Handbook and Formulary. Toronto, ON.
11. Prasad P, Nania JJ, Shankar SM. Pneumocystis pneumonia in children receiving chemotherapy. Pediatric Blood & Cancer. 2008;50:896-898.
12. Kim SY, Dabb AA, Glenn DJ, et al. Intravenous pentamidine is effective as second line pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatric Blood & Cancer. 2008;50:779-783.
13. CDC: Guidelines for prophylaxis against pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001957. htm. Accessed January 12, 2011.
14. Williams S, MacDonald P, Hoyer JD, et al. Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: A correlation with cytochrome b5 reductase (CB5R) enzyme levels. Cancer. 2005;44:55-62.
15. Chuk MK, Dabb AA, Kim SY, et al. The use of IV pentamidine as second line prophylaxis for pneumocystis pneumonia. Journal of Clinical Oncology. 2006 ASCO Annual Meeting Proceedings Part I;24(18 S):9043.
16. PCP prophylaxis: What to do when SMX/TMS fails? http://www.isopporg/files/education…/Rao%20PCP%20Prophylxais%20Final.pdf Accessed February 26, 2011.
17. Pneumocystiscariniipneumonia. http://www.medicine.gerogetown.edu/residency/BoardReview/PCP.PPT. Accessed February 26, 2011.
18. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and metaanalysis. Journal of Clinical Oncology. 2007;25:5471-5489.
19. Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy patients. Cancer. 2002;94:3230-3246.
20. Groll AH, Just-Nuebling G, Kurz M, et al. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. Journal of Antimicrobial Chemotherapy. 1997;40:855-862.
21. NCCN Practice guidelines in oncology: Prevention and treatment of cancer-related infections. http://www.oralcancerfoundationorg./treatment/pdf/infections-NCCN.pdf. Accessed February 26, 2011.
22. nded. New York, NY: Springer-Verlag Berlin Heidelberg;2010:515-528.
23. Clark OAC, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy- induced febrile neutropenia: A meta-analysis of randomized controlled trials. Journal of Clinical Oncology. 2005;23(18):4198-4214.
24. Bukowski R. Cytoprotection in the treatment of pediatric cancer: Review of current strategies in adults and their application to children. Medical and Pediatric Oncology. 1999;32:124-134.
25. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. Journal of Clinical Oncology. 2006;24(19):3187-3205.
26. Martin-Johnston MK, Okoji OY, Armstrong A. Therapeutic amenorrhea in patients at risk for thrombocytopenia. Obstetrical and Gynecological Survey. 2008;63(6):395-401.
27. Extended and continuous use of contraceptives to reduce menstruation. http://www.arhp.org/Publications-and-Resources/Clinical-Proceedings/Reduce-Menses. Accessed January 12, 2011.
28. Fisher WA, Black A. Contraception in Canada: A review of method choices, characteristics, adherence and approaches to counseling. CMAJ. 2007;176(7):953-961.
29. Hillard PJA. Therapeutic amenorrhea. Journal of Pediatric Hematology/Oncology. 1999;21(5): 350-352.